Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
出版年份 2018 全文链接
标题
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
作者
关键词
-
出版物
ENDOCRINE-RELATED CANCER
Volume -, Issue -, Pages 227-239
出版商
Bioscientifica
发表日期
2018-12-12
DOI
10.1530/erc-18-0424
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
- (2018) Halfdan Sorbye et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index
- (2018) Silvia Nicolini et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
- (2017) T. Walter et al. EUROPEAN JOURNAL OF CANCER
- Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis
- (2017) Sue Ping Thang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas
- (2017) Angela Lamarca et al. JNCI-Journal of the National Cancer Institute
- Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%
- (2017) Björn Konukiewitz et al. MODERN PATHOLOGY
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
- (2017) Rodney J. Hicks et al. NEUROENDOCRINOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology
- (2017) Nitya Raj et al. PANCREAS
- Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas
- (2017) Angela Lamarca et al. JNCI-Journal of the National Cancer Institute
- A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas
- (2016) Laura H. Tang et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories
- (2016) Massimo Milione et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
- (2016) R. Garcia-Carbonero et al. NEUROENDOCRINOLOGY
- The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
- (2015) Olca Basturk et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
- (2015) J. Hadoux et al. ENDOCRINE-RELATED CANCER
- Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
- (2015) M Heetfeld et al. ENDOCRINE-RELATED CANCER
- Gastroenteropancreatic high-grade neuroendocrine carcinoma
- (2014) Halfdan Sorbye et al. CANCER
- Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system
- (2014) Tomohiro Yamaguchi et al. CANCER SCIENCE
- Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
- (2014) Raghava Kashyap et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
- (2014) Ingrid Holst Olsen et al. Journal of Cancer
- Are G3 ENETS neuroendocrine neoplasms heterogeneous?
- (2013) Fritz-Line Vélayoudom-Céphise et al. ENDOCRINE-RELATED CANCER
- Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours
- (2013) A. Romer et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
- (2012) H. Sorbye et al. ANNALS OF ONCOLOGY
- FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3
- (2012) O Hentic et al. ENDOCRINE-RELATED CANCER
- Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy
- (2011) Staffan Welin et al. CANCER
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
- (2011) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
- (2011) Anna Imhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland
- (2011) Andreas Klaus Pfeifer et al. NEUROENDOCRINOLOGY
- Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET
- (2010) T. Binderup et al. JOURNAL OF NUCLEAR MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started